The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.
Patients eligible for the study, after signing informed consent will be randomized 1:1 for
maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy
for other classes according to a pre-specified protocol.
Patients are going to be followed during hospital stay for evaluation of clinical endpoints.
Also blood and urine samples will be acquired for evaluation of renin-angiotensin system
activation.
Drug: Renin-angiotensin system inhibitors
switch anti-hypertensive class
Inclusion Criteria:
- Hypertension in use of renin-angiotensin system inhibitors
- Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical
presentation and chest CT.
- Symptoms onset < 96h
- Need for hospitalization
Exclusion Criteria:
- Heart failure
- Previous cerebrovascular disease
- Previous myocardial infarction
- Blood pressure > 180 x 100 mmHg
- Need for 3 or more anti-hypertensive classes
- Use os spironolactone
- Severe pulmonary disease
- Contraindication for using other anti-hypertensive classes (calcium channel blockers,
hydralazine, diuretics or nitrates)
Instituto do Coração - Incor HCFMUSP
São Paulo, SP, Brazil